Clinical Evaluation of S-3470

Ritsuko Hayakawa, Kayoko Matsunaga, Mari Suzuki, Kaori Hosokawa

Research output: Contribution to journalArticlepeer-review


S-3470 contains 0.025% dexamethasone 21 acetate, 0.1% chlorhexidine dihydrochloride, 0.3% glycyrrhizic acid and 0.5% tocopherol acetate, and the main component of its vehicle is petrolatum. S-3470 was designed for an OTC drug. We clinically evaluated S-3470 on 41 patients with skin diseases such as eczema, dermatitis and insect bite. We obseved the patients for 3 weeks and we could take significant improvement in 92.3% cases with eczema or dermatitis and in 100% cases with insect bite. No adverse effects such as telangiectasis, redness, acne like eruptions were seen. So we decided that S-3470 was an usefull ointment.

Original languageEnglish
Pages (from-to)663-670
Number of pages8
Journalskin research
Issue number3
Publication statusPublished - 01-01-1987
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Dermatology
  • Infectious Diseases


Dive into the research topics of 'Clinical Evaluation of S-3470'. Together they form a unique fingerprint.

Cite this